Strs Ohio Reduces Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Strs Ohio lowered its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 75.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 17,300 shares of the biopharmaceutical company’s stock after selling 53,600 shares during the period. Strs Ohio’s holdings in Amicus Therapeutics were worth $245,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vontobel Holding Ltd. purchased a new position in Amicus Therapeutics in the 4th quarter worth $1,173,000. Mutual of America Capital Management LLC boosted its position in Amicus Therapeutics by 27.3% in the fourth quarter. Mutual of America Capital Management LLC now owns 217,859 shares of the biopharmaceutical company’s stock valued at $3,091,000 after buying an additional 46,762 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Amicus Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 229,604 shares of the biopharmaceutical company’s stock valued at $3,258,000 after buying an additional 19,204 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Amicus Therapeutics by 360.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,920 shares of the biopharmaceutical company’s stock worth $481,000 after buying an additional 26,552 shares during the period. Finally, Diversified Trust Co raised its position in Amicus Therapeutics by 8.0% during the 4th quarter. Diversified Trust Co now owns 62,695 shares of the biopharmaceutical company’s stock worth $890,000 after buying an additional 4,633 shares during the last quarter.

Insider Buying and Selling

In other Amicus Therapeutics news, Director Margaret G. Mcglynn sold 7,500 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $13.40, for a total transaction of $100,500.00. Following the transaction, the director now owns 59,289 shares in the company, valued at $794,472.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider David Michael Clark sold 4,427 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $14.00, for a total value of $61,978.00. Following the completion of the sale, the insider now owns 253,664 shares of the company’s stock, valued at approximately $3,551,296. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Margaret G. Mcglynn sold 7,500 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $13.40, for a total transaction of $100,500.00. Following the transaction, the director now owns 59,289 shares of the company’s stock, valued at $794,472.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 48,108 shares of company stock valued at $662,605. 2.10% of the stock is owned by company insiders.

Amicus Therapeutics Stock Performance

FOLD opened at $10.25 on Tuesday. The firm has a fifty day moving average price of $11.81 and a 200 day moving average price of $12.00. Amicus Therapeutics, Inc. has a 1 year low of $9.70 and a 1 year high of $14.57. The stock has a market cap of $3.04 billion, a P/E ratio of -20.10 and a beta of 0.75. The company has a debt-to-equity ratio of 2.42, a current ratio of 2.88 and a quick ratio of 2.52.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). Amicus Therapeutics had a negative return on equity of 119.46% and a negative net margin of 37.96%. The firm had revenue of $115.08 million during the quarter, compared to analyst estimates of $115.11 million. Equities research analysts anticipate that Amicus Therapeutics, Inc. will post 0.01 earnings per share for the current year.

Analyst Ratings Changes

FOLD has been the topic of a number of research reports. JPMorgan Chase & Co. cut their price objective on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Monday, March 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $22.00 price target on shares of Amicus Therapeutics in a research report on Thursday, February 29th.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.